Summary Safety Review - Loratadine - Abnormal heart rhythm (QT interval prolongation)
Health Canada carried out a safety review to investigate the potential risk of developing an abnormal heart rhythm (QT interval prolongation) with the use of over-the-counter (OTC) drug products containing loratadine. This safety review was triggered by a publication, in the World Health Organization (WHO) Pharmaceuticals NewsletterFootnote1, describing cases of an abnormal heart rhythm (QT interval prolongation) possibly associated with the use of loratadine and desloratadine.
- Publisher - Current Organization Name: Health Canada
- Licence: Open Government Licence - Canada
Data and Resources
-
Summary Safety Review - Loratadine - Abnormal heart rhythm (QT interval prolongation)HTMLEnglish publication HTML
-
Summary Safety Review - Loratadine - Abnormal heart rhythm (QT interval prolongation)HTMLEnglish publication HTML
-
Summary Safety Review - Loratadine - Abnormal heart rhythm (QT interval prolongation)HTMLFrench publication HTML
Similar records